Full Transcript Nerve Pain and the Promise of ARA-290 0:01 Imagine: 0:01 Imagine: your feet are burning at night, your 0:02 your feet are burning at night, your 0:02 your feet are burning at night, your fingertips are 0:03 fingertips are 0:03 fingertips are tingling, and your 0:04 tingling, and your 0:04 tingling, and your test results are 0:05 test results are 0:06 test results are normal every time. The medications you 0:07 normal every time. The medications you 0:07 normal every time. The medications you take 0:07 take 0:07 take mostly only 0:08 mostly only 0:08 mostly only dull the pain, but the 0:09 dull the pain, but the 0:09 dull the pain, but the damaged nerve 0:10 damaged nerve 0:10 damaged nerve remains in the same 0:11 remains in the same 0:11 remains in the same condition. Now imagine a 0:12 condition. Now imagine a 0:12 condition. Now imagine a peptide designed for a 0:13 peptide designed for a 0:14 peptide designed for a different purpose—to 0:14 different purpose—to 0:14 different purpose—to command those nerves 0:15 command those nerves 0:15 command those nerves to repair themselves. This is the 0:17 to repair themselves. This is the 0:17 to repair themselves. This is the main promise of ARA 290 0:19 main promise of ARA 290 . In today's 0:20 . In today's 0:20 . In today's video, I'll explain what it is 0:21 video, I'll explain what it is 0:21 video, I'll explain what it is , how it's supposed to 0:21 , how it's supposed to 0:22 , how it's supposed to work, and 0:22 work, and 0:22 work, and how much of this 0:23 how much of this 0:23 how much of this promise is backed up by 0:24 promise is backed up by 0:24 promise is backed up by research. Welcome 0:25 research. Welcome 0:25 research. Welcome to the podcast " 0:25 to the podcast " 0:27 Dr. Jones' Optimization Academy." I'm 0:27 Dr. Jones' Optimization Academy." I'm Dr. Greg Jones, a 0:28 Dr. Greg Jones, a 0:28 Dr. Greg Jones, a naturopath and 0:29 naturopath and 0:29 naturopath and founder of 0:30 founder of 0:30 founder of Innovate Wellness Center here in 0:31 Innovate Wellness Center here in 0:31 Innovate Wellness Center here in Phoenix, Arizona 0:32 Phoenix, Arizona . I lecture 0:33 . I lecture 0:33 . I lecture and teach around the world 0:34 and teach around the world 0:34 and teach around the world on 0:35 on 0:35 on peptides, 0:35 peptides, 0:35 peptides, hormone optimization, 0:36 hormone optimization, 0:36 hormone optimization, and 0:37 and 0:37 and longevity medicine. Today 0:38 longevity medicine. Today 0:38 longevity medicine. Today we will 0:39 we will 0:39 we will take a detailed look at ARA 290. 0:40 take a detailed look at ARA 290. 0:40 take a detailed look at ARA 290. As a reminder, this is educational 0:41 As a reminder, this is educational 0:41 As a reminder, this is educational content, not medical 0:42 content, not medical 0:42 content, not medical advice, so please consult your doctor before 0:43 advice, so please consult your doctor before 0:43 advice, so please consult your doctor before making any 0:44 making any 0:44 making any decisions 0:44 decisions 0:47 . So,
What ARA-290 Is and How It Works 0:48 . So, let's start with a description of ARA 290 0:49 let's start with a description of ARA 290 0:49 let's start with a description of ARA 290 and its principle of operation. 0:51 and its principle of operation. 0:51 and its principle of operation. You may have heard of 0:52 You may have heard of 0:52 You may have heard of erythropoietin, or EPO, a 0:52 erythropoietin, or EPO, a hormone that some 0:53 hormone that some 0:53 hormone that some athletes have 0:54 athletes have 0:54 athletes have used to 0:55 used to 0:55 used to increase 0:55 increase 0:56 increase red blood cell count to 0:56 red blood cell count to 0:56 red blood cell count to improve performance 0:57 improve performance 0:57 improve performance and endurance. It's 0:58 and endurance. It's 0:58 and endurance. It's produced by your 0:59 produced by your 0:59 produced by your kidneys, but it also has 1:00 kidneys, but it also has 1:00 kidneys, but it also has another function unrelated 1:01 another function unrelated 1:01 another function unrelated to red 1:01 to red 1:01 to red blood cells. This is 1:02 blood cells. This is 1:02 blood cells. This is to protect your tissues, 1:03 to protect your tissues, 1:03 to protect your tissues, particularly your nerves, in 1:04 particularly your nerves, in 1:04 particularly your nerves, in case they are damaged. A 1:05 case they are damaged. A 1:07 blood-thinning drug is a bad idea 1:07 blood-thinning drug is a bad idea for someone who already 1:08 for someone who already 1:08 for someone who already has inflammation. 1:09 has inflammation. 1:09 has inflammation. So the researchers 1:10 So the researchers 1:10 So the researchers took a small 1:11 took a small 1:11 took a small fragment of EPO made up of 11 1:11 fragment of EPO made up of 11 1:11 fragment of EPO made up of 11 amino acids and 1:12 amino acids and 1:12 amino acids and created a version that 1:13 created a version that 1:13 created a version that retains its protective 1:14 retains its protective 1:14 retains its protective properties but does not 1:14 properties but does not 1:14 properties but does not stimulate 1:15 stimulate 1:15 stimulate red blood cell production. This 1:16 red blood cell production. This 1:16 red blood cell production. This fragment—ARA 290, also 1:18 fragment—ARA 290, also 1:18 fragment—ARA 290, also known as sebinetide. 1:19 known as sebinetide. 1:19 known as sebinetide. This is how 1:20 This is how 1:21 This is how this division of functions should work. 1:22 this division of functions should work. 1:22 this division of functions should work. EPO acts through the 1:22 EPO acts through the 1:23 EPO acts through the erythropoietin 1:23 erythropoietin 1:23 erythropoietin receptor, and the result of 1:25 receptor, and the result of 1:25 receptor, and the result of its work depends 1:26 its work depends 1:26 its work depends on the partner. When 1:27 on the partner. When 1:27 on the partner. When two EPO receptors 1:28 two EPO receptors 1:28 two EPO receptors combine, the signal 1:29 combine, the signal 1:29 combine, the signal to the bone marrow is 1:30 to the bone marrow is to produce red blood cells 1:31 to produce red blood cells . When the 1:32 . When the 1:32 . When the erythropoietin 1:33 erythropoietin 1:33 erythropoietin receptor 1:33 receptor 1:33 receptor combines with another 1:34 combines with another 1:34 combines with another partner—the general 1:35 partner—the general 1:35 partner—the general beta receptor— 1:36 beta receptor— 1:36 beta receptor— the signal changes to 1:37 the signal changes to 1:37 the signal changes to “protect and 1:38 “protect and 1:38 “protect and repair.” The 1:38 repair.” The 1:38 repair.” The developers called 1:39 developers called 1:39 developers called this second combination the “ 1:40 this second combination the “ 1:41 innate 1:41 innate repair receptor” and 1:42 repair receptor” and 1:42 repair receptor” and hypothesized that it 1:42 hypothesized that it 1:42 hypothesized that it appears 1:43 appears 1:43 appears primarily on 1:43 primarily on 1:43 primarily on cells that are 1:44 cells that are 1:44 cells that are damaged, inflamed, 1:45 damaged, inflamed, 1:45 damaged, inflamed, or under 1:46 or under 1:46 or under metabolic 1:46 metabolic 1:46 metabolic stress—precisely where 1:47 stress—precisely where 1:47 stress—precisely where repair is needed 1:48 repair is needed . ARA 290 is designed to 1:49 . ARA 290 is designed to interact 1:50 interact 1:50 interact specifically with this second 1:51 specifically with this second 1:51 specifically with this second type of compound, 1:52 type of compound, 1:52 type of compound, bypassing the first. 1:53 bypassing the first. 1:53 bypassing the first. After docking, 1:54 After docking, 1:54 After docking, the cell 1:54 the cell 1:55 the cell receives two 1:55 receives two 1:55 receives two instructions simultaneously. The first is to 1:56 instructions simultaneously. The first is to calm down. 1:57 calm down. 1:57 calm down. ARA 290 is reported to 1:58 ARA 290 is reported to 1:58 ARA 290 is reported to inhibit inflammatory 1:59 inhibit inflammatory 1:59 inhibit inflammatory messengers such as 2:00 messengers such as 2:02 tumor necrosis factor alpha and 2:02 tumor necrosis factor alpha and interleukin-1 beta. And 2:03 interleukin-1 beta. And 2:03 interleukin-1 beta. And it affects 2:04 it affects 2:04 it affects activated microglia 2:05 activated microglia —these are immune cells in 2:06 —these are immune cells in 2:06 —these are immune cells in the brain and 2:06 the brain and 2:06 the brain and spinal cord that 2:07 spinal cord that 2:07 spinal cord that remain in 2:08 remain in 2:08 remain in attack mode after injury and 2:09 attack mode after injury and 2:09 attack mode after injury and constantly generate 2:10 constantly generate 2:10 constantly generate pain signals. This is 2:11 pain signals. This is 2:11 pain signals. This is important with 2:12 important with 2:12 important with nerve pain 2:12 nerve pain 2:12 nerve pain because prolonged 2:13 because prolonged 2:13 because prolonged inflammation is what 2:14 inflammation is what 2:14 inflammation is what makes the pain persist 2:15 makes the pain persist 2:15 makes the pain persist over and over again. The second 2:17 over and over again. The second 2:17 over and over again. The second instruction is to survive and 2:18 instruction is to survive and 2:18 instruction is to survive and recover, and this is where 2:19 recover, and this is where 2:21 nerve fibers come into play. 2:21 nerve fibers come into play. Imagine a smoke detector 2:22 Imagine a smoke detector 2:22 Imagine a smoke detector that only goes off when 2:23 that only goes off when 2:23 that only goes off when something 2:24 something 2:24 something starts to burn. 2:25 starts to burn. 2:25 starts to burn. Think of ARA as a finger on a 2:26 Think of ARA as a finger on a 2:26 Think of ARA as a finger on a test button. 2:27 test button. 2:28 test button. Press this 2:28 Press this 2:28 Press this button, and the inflammation 2:29 button, and the inflammation 2:29 button, and the inflammation should subside, and the 2:30 should subside, and the 2:30 should subside, and the damaged nerve 2:31 damaged nerve 2:31 damaged nerve fibers will receive a 2:32 fibers will receive a 2:32 fibers will receive a stimulus for 2:32 stimulus for 2:32 stimulus for regeneration. It is worth 2:33 regeneration. It is worth 2:33 regeneration. It is worth noting that this 2:34 noting that this 2:34 noting that this receptor was 2:34 receptor was 2:34 receptor was described by the 2:35 described by the 2:35 described by the 2:37 drug developers. And in 2018, an 2:37 drug developers. And in 2018, an independent 2:37 independent 2:37 independent laboratory was 2:38 laboratory was 2:38 laboratory was unable to confirm the 2:39 unable to confirm the 2:39 unable to confirm the physical bonding of 2:40 physical bonding of 2:40 physical bonding of these two parts. So 2:41 these two parts. So 2:41 these two parts. So this is just a working 2:41 this is just a working 2:41 this is just a working hypothesis that 2:42 hypothesis that 2:42 hypothesis that fits 2:42 fits 2:42 fits the results, but the 2:43 the results, but the 2:43 the results, but the biological side of 2:43 biological side of 2:44 biological side of the issue is not yet 2:44 the issue is not yet 2:44 the issue is not yet fully understood. What
Potential Benefits for Small Fiber Neuropathy 2:45 fully understood. What 2:45 fully understood. What could all this mean 2:46 could all this mean 2:46 could all this mean for Somanadi? The most 2:47 for Somanadi? The most 2:47 for Somanadi? The most obvious target is 2:48 obvious target is small 2:49 small 2:49 small fiber neuropathy. This is 2:50 fiber neuropathy. This is 2:50 fiber neuropathy. This is damage to 2:50 damage to 2:50 damage to the finest nerve 2:51 the finest nerve 2:51 the finest nerve fibers in the body 2:52 fibers in the body 2:52 fibers in the body that transmit 2:52 that transmit 2:52 that transmit sensations of burning, 2:53 sensations of burning, 2:53 sensations of burning, temperature, and 2:54 temperature, and 2:54 temperature, and automatic signals 2:54 automatic signals 2:54 automatic signals that control 2:55 that control 2:55 that control digestion and 2:55 digestion and 2:55 digestion and heartbeat. This 2:56 heartbeat. This 2:56 heartbeat. This damage 2:57 damage 2:57 damage is exacerbated by 2:57 is exacerbated by 2:57 is exacerbated by sarcoidosis, diabetes, 2:58 sarcoidosis, diabetes, 2:58 sarcoidosis, diabetes, and sometimes occurs without any 2:59 and sometimes occurs without any 2:59 and sometimes occurs without any clear cause. 3:00 clear cause. 3:00 clear cause. The theory is 3:01 The theory is that ARA 290 doesn't just 3:02 that ARA 290 doesn't just 3:02 that ARA 290 doesn't just dull the 3:03 dull the 3:03 dull the burning sensation. It 3:04 burning sensation. It 3:04 burning sensation. It can really help 3:05 can really help 3:05 can really help repair damaged 3:06 repair damaged 3:06 repair damaged nerve fibers. 3:06 nerve fibers. 3:07 nerve fibers. Diabetes adds another 3:08 Diabetes adds another 3:08 Diabetes adds another possibility. In one 3:09 possibility. In one 3:09 possibility. In one study, people with 3:10 study, people with 3:10 study, people with type 2 diabetes 3:10 type 2 diabetes 3:10 type 2 diabetes experienced improvements in 3:11 experienced improvements in 3:13 blood sugar and triglyceride levels along with a 3:13 blood sugar and triglyceride levels along with a reduction in neuropathy symptoms, 3:14 reduction in neuropathy symptoms, 3:15 hinting at the 3:15 hinting at the peptide’s ability to affect 3:16 peptide’s ability to affect 3:16 peptide’s ability to affect metabolism and 3:16 metabolism and 3:16 metabolism and nerve repair 3:17 nerve repair 3:17 nerve repair simultaneously. I also want to 3:18 simultaneously. I also want to 3:18 simultaneously. I also want to mention a list of 3:19 mention a list of 3:19 mention a list of potential benefits 3:20 potential benefits 3:20 potential benefits that research 3:20 that research 3:20 that research may confirm in 3:21 may confirm in 3:21 may confirm in the future. 3:22 the future. 3:22 the future. Recovery from 3:22 Recovery from 3:22 Recovery from brain injuries, recovery 3:23 brain injuries, recovery 3:23 brain injuries, recovery from heart 3:24 from heart 3:24 from heart attacks, chronic 3:25 attacks, chronic 3:25 attacks, chronic fatigue, and 3:26 fatigue, and 3:26 fatigue, and nerve damage from 3:26 nerve damage from 3:26 nerve damage from chemotherapy. These ideas are 3:27 chemotherapy. These ideas are 3:27 chemotherapy. These ideas are mostly 3:28 mostly 3:28 mostly based on 3:28 based on 3:29 animal studies and 3:29 animal studies and mechanisms of action, so 3:30 mechanisms of action, so 3:30 mechanisms of action, so take them as 3:31 take them as 3:31 take them as exciting 3:31 exciting 3:31 exciting prospects rather than as 3:32 prospects rather than as 3:32 prospects rather than as available benefits 3:33 available benefits 3:33 available benefits today. I understand. 3:34 today. I understand. 3:34 today. I understand. Choosing supplements can 3:35 Choosing supplements can 3:35 Choosing supplements can be exhausting. 3:36 be exhausting. 3:36 be exhausting. There are hundreds of 3:37 There are hundreds of 3:37 There are hundreds of brands, conflicting 3:38 brands, conflicting 3:38 brands, conflicting claims, and it's impossible 3:39 claims, and it's impossible 3:39 claims, and it's impossible to understand what's 3:40 to understand what's 3:40 to understand what's actually high-quality and what will 3:41 actually high-quality and what will 3:41 actually high-quality and what will truly make a difference in 3:42 truly make a difference in 3:42 truly make a difference in your health. That's 3:43 your health. That's 3:43 your health. That's why I created 3:44 why I created 3:46 Dr. Jones Supplement Store. Every 3:46 Dr. Jones Supplement Store. Every product in the store 3:47 product in the store 3:47 product in the store for energy, 3:47 for energy, 3:47 for energy, gut health, 3:48 gut health, 3:48 gut health, sleep, 3:49 sleep, 3:49 sleep, hormone optimization, 3:49 hormone optimization, 3:49 hormone optimization, recovery, and 3:50 recovery, and 3:50 recovery, and more— 3:50 more— has been personally reviewed 3:51 has been personally reviewed , tested, and 3:52 , tested, and 3:52 , tested, and recommended by me. 3:53 recommended by me. 3:53 recommended by me. These are the exact formulas 3:54 These are the exact formulas 3:54 These are the exact formulas I use and 3:55 I use and 3:55 I use and recommend to my 3:56 recommend to my 3:56 recommend to my patients, friends, and 3:56 patients, friends, and 3:56 patients, friends, and family. So go 3:57 family. So go 3:57 family. So go to drjoessupplements.com, 3:58 to drjoessupplements.com, 3:58 to drjoessupplements.com, sign up for the 3:59 sign up for the 3:59 sign up for the newsletter, and you'll 4:00 newsletter, and you'll 4:00 newsletter, and you'll get 10% off 4:00 get 10% off 4:01 get 10% off your first 4:01 your first 4:01 your first order. You will also 4:02 order. You will also 4:02 order. You will also gain access to 4:03 gain access to 4:03 gain access to exclusive 4:03 exclusive 4:03 exclusive protocols and 4:04 protocols and 4:04 protocols and insights that I 4:04 insights that I 4:04 insights that I share only with my 4:05 share only with my 4:05 share only with my community. So let's 4:06 community. So let's 4:06 community. So let's cut through the noise 4:07 cut through the noise 4:07 cut through the noise and choose what 4:07 and choose what 4:07 and choose what really works. 4:08 really works. 4:08 really works. So what does
Clinical Trial Results Reviewed 4:09 So what does 4:09 So what does current research show? 4:10 current research show? 4:10 current research show? The best results 4:11 The best results 4:11 The best results came from 4:12 came from 4:12 came from the Netherlands. In 2012, 4:13 the Netherlands. In 2012, 4:13 the Netherlands. In 2012, 22 patients with 4:14 22 patients with 4:14 22 patients with sarcoidosis and 4:14 sarcoidosis and 4:14 sarcoidosis and small 4:16 small 4:16 small fiber neuropathy received ARA 4:17 fiber neuropathy received ARA 4:17 fiber neuropathy received ARA 290 intravenously 4:18 290 intravenously 4:18 290 intravenously for 4 weeks and 4:19 for 4 weeks and 4:19 for 4 weeks and reported 4:19 reported 4:19 reported significant improvement in 4:20 significant improvement in 4:20 significant improvement in symptoms compared 4:21 symptoms compared 4:21 symptoms compared to placebo. And in 2013, 4:23 to placebo. And in 2013, 4:23 to placebo. And in 2013, 38 patients 4:24 38 patients 4:24 38 patients were given daily subcutaneous 4:26 were given daily subcutaneous 4:26 were given daily subcutaneous injections of ARA 290. After 28 4:27 injections of ARA 290. After 28 4:27 injections of ARA 290. After 28 days, photographs of 4:28 days, photographs of 4:28 days, photographs of the surface of the eye 4:28 the surface of the eye 4:28 the surface of the eye showed an increase in 4:29 showed an increase in 4:29 showed an increase in the number of nerve 4:30 the number of nerve 4:30 the number of nerve fibers, the patients 4:31 fibers, the patients 4:31 fibers, the patients could walk 4:31 could walk 4:31 could walk longer distances, and 4:32 longer distances, and 4:32 longer distances, and their symptoms 4:33 their symptoms 4:33 their symptoms improved. The 4:33 improved. The 4:33 improved. The largest 4:34 largest 4:34 largest study in 2017 4:35 study in 2017 4:35 study in 2017 tested three 4:36 tested three 4:36 tested three dosages in 64 4:37 dosages in 64 4:37 dosages in 64 patients. And only 4:38 patients. And only 4:38 patients. And only a dose of 4 mg per day 4:39 a dose of 4 mg per day 4:39 a dose of 4 mg per day statistically significantly 4:40 statistically significantly 4:40 statistically significantly increased the area of 4:41 increased the area of 4:41 increased the area of nerve fibers in the 4:42 nerve fibers in the 4:42 nerve fibers in the cornea. 4:43 cornea. 4:43 cornea. Skin biopsy showed 4:44 Skin biopsy showed 4:44 Skin biopsy showed more fibers in the 4:44 more fibers in the 4:44 more fibers in the healing process, 4:45 healing process, 4:45 healing process, and pain decreased in 4:46 and pain decreased in 4:46 and pain decreased in all groups. And in 4:47 all groups. And in 4:47 all groups. And in 4:48 study participants who 4:48 study participants who started with moderate 4:49 started with moderate 4:49 started with moderate to severe pain, the 4:50 to severe pain, the 4:50 to severe pain, the 4 4:51 4 4:51 4 mg group outperformed 4:52 mg group outperformed 4:52 mg group outperformed placebo by a significant 4:53 placebo by a significant 4:53 placebo by a significant margin, although it did 4:54 margin, although it did 4:54 margin, although it did not reach 4:54 not reach 4:54 not reach statistical 4:55 statistical 4:55 statistical significance. In 48 people 4:56 significance. In 48 people 4:56 significance. In 48 people with painful 4:57 with painful 4:57 with painful diabetic 4:57 diabetic 4:57 diabetic neuropathy, a 28-day 4:59 neuropathy, a 28-day 4:59 neuropathy, a 28-day course of 4 mg improved 5:00 course of 4 mg improved 5:00 course of 4 mg improved nerve symptoms, 5:01 nerve symptoms, 5:01 nerve symptoms, hemoglobin A1C, 5:02 hemoglobin A1C, 5:02 hemoglobin A1C, and triglyceride levels. And 5:03 and triglyceride levels. And 5:03 and triglyceride levels. And these changes persisted 5:04 these changes persisted 5:04 these changes persisted for a month after the 5:05 for a month after the 5:05 for a month after the last dose. These 5:06 last dose. These 5:06 last dose. These studies were 5:07 studies were 5:07 studies were small and 5:07 small and 5:07 small and short-term, so 5:08 short-term, so 5:08 short-term, so they best 5:08 they best 5:08 they best serve as a basis for 5:09 serve as a basis for 5:09 serve as a basis for larger 5:10 larger 5:10 larger trials. Also 5:10 trials. Also 5:10 trials. Also , just to be 5:11 , just to be 5:11 , just to be clear, ARA 290 is not 5:11 clear, ARA 290 is not 5:12 clear, ARA 290 is not FDA-approved to 5:12 FDA-approved to 5:12 FDA-approved to treat any 5:13 treat any 5:13 treat any conditions, and it has never 5:14 conditions, and it has never 5:14 conditions, and it has never progressed beyond 5:14 progressed beyond 5:14 progressed beyond phase two 5:15 phase two 5:15 phase two clinical 5:15 clinical 5:15 clinical trials. So nothing 5:16 trials. So nothing 5:16 trials. So nothing we 5:16 we 5:16 we talk about today 5:17 talk about today 5:17 talk about today guarantees the purity, 5:18 guarantees the purity, 5:18 guarantees the purity, dosage, or 5:18 dosage, or 5:18 dosage, or results of any 5:19 results of any 5:19 results of any products 5:20 products 5:20 products sold under this 5:20 sold under this 5:20 sold under this name. Now regarding 5:21 name. Now regarding 5:21 name. Now regarding dosage: here is what
Dosing Protocols From the Research 5:22 dosage: here is what 5:22 dosage: here is what was used in 5:23 was used in 5:23 was used in those trials. In the 5:24 those trials. In the 5:24 those trials. In the very first 5:24 very first 5:24 very first study, 2 mg was administered 5:25 study, 2 mg was administered 5:25 study, 2 mg was administered intravenously 5:26 intravenously 5:26 intravenously three times a week. 5:27 three times a week. 5:27 three times a week. After that, 5:27 After that, 5:30 4 mg 5:30 4 mg per day subcutaneously 5:31 per day subcutaneously 5:31 per day subcutaneously for 28 days was used in trials in sarcoidosis and diabetes. The 5:32 for 28 days was used in trials in sarcoidosis and diabetes. The 5:32 for 28 days was used in trials in sarcoidosis and diabetes. The same dose 5:32 same dose 5:32 same dose was used 5:33 was used 5:33 was used for 12 weeks in a 5:33 for 12 weeks in a 5:33 for 12 weeks in a small 5:34 small 5:34 small eye study. In 5:35 eye study. In 5:35 eye study. In those studies, 8 mg did 5:36 those studies, 8 mg did 5:36 those studies, 8 mg did not produce better 5:37 not produce better 5:37 not produce better results than 4 mg. 5:38 results than 4 mg. 5:38 results than 4 mg. There are currently no 5:39 There are currently no 5:39 There are currently no published data 5:40 published data 5:40 published data on repeat 5:41 on repeat 5:41 on repeat courses, so any 5:42 courses, so any 5:42 courses, so any treatment beyond 12 5:42 treatment beyond 12 5:42 treatment beyond 12 weeks is 5:43 weeks is 5:43 weeks is an assumption that 5:44 an assumption that 5:44 an assumption that the clinician must 5:44 the clinician must 5:44 the clinician must tailor to you 5:45 tailor to you 5:45 tailor to you or the patient 5:46 or the patient 5:46 or the patient they are treating. What about
Safety Profile and Contraindications 5:47 they are treating. What about 5:47 they are treating. What about security? 5:48 security? 5:48 security? No 5:49 No 5:50 serious 5:50 serious safety issues were reported in the trials, and 5:51 safety issues were reported in the trials, and 5:51 safety issues were reported in the trials, and eye testing did not 5:52 eye testing did not 5:52 eye testing did not detect antibodies to 5:53 detect antibodies to 5:53 detect antibodies to the drug. A typical 5:53 the drug. A typical 5:53 the drug. A typical complaint was mild 5:54 complaint was mild 5:54 complaint was mild redness or 5:55 redness or 5:55 redness or discomfort at the 5:56 discomfort at the 5:56 discomfort at the injection site. The level of 5:57 injection site. The level of 5:57 injection site. The level of erythrocytes did not increase 5:58 erythrocytes did not increase 5:58 erythrocytes did not increase significantly during the tests 5:59 significantly during the tests 5:59 significantly during the tests . 6:00 . 6:00 . One study 6:01 One study 6:01 One study reported a 6:01 reported a 6:01 reported a fatal heart 6:02 fatal heart 6:02 fatal heart attack and a case of 6:03 attack and a case of 6:03 attack and a case of worsening 6:04 worsening 6:04 worsening kidney function, but the researchers 6:05 kidney function, but the researchers 6:05 kidney function, but the researchers did not link these to 6:06 did not link these to 6:06 did not link these to ARA 290. 6:06 ARA 290. 6:06 ARA 290. The longest period 6:07 The longest period 6:07 The longest period of observation in 6:08 of observation in 6:08 of observation in humans was 12 6:09 humans was 12 6:09 humans was 12 weeks, so 6:09 weeks, so 6:11 effects that 6:11 effects that appear 6:11 appear 6:11 appear years later cannot be ruled out. There are no official contraindications at this time 6:12 years later cannot be ruled out. There are no official contraindications at this time 6:12 years later cannot be ruled out. There are no official contraindications at this time 6:14 . 6:14 . There are only considerations 6:15 There are only considerations 6:15 There are only considerations based on 6:15 based on 6:15 based on the properties of the 6:16 the properties of the 6:16 the properties of the original hormone and the 6:17 original hormone and the 6:17 original hormone and the results of 6:17 results of 6:17 results of the patients studied. Therefore, 6:18 the patients studied. Therefore, 6:18 the patients studied. Therefore, active cancer or 6:19 active cancer or 6:19 active cancer or 6:20 recent cancer is a 6:20 recent cancer is a potential reason 6:21 potential reason 6:21 potential reason to avoid ARA 290, 6:22 to avoid ARA 290, 6:22 to avoid ARA 290, as there 6:22 as there 6:22 as there is a long-standing 6:23 is a long-standing 6:23 is a long-standing debate about EPO's 6:24 debate about EPO's 6:24 debate about EPO's tumor growth. Unstable 6:25 tumor growth. Unstable 6:25 tumor growth. Unstable heart disease, a 6:25 heart disease, a 6:25 heart disease, a recent heart 6:26 recent heart 6:26 recent heart attack, or 6:26 attack, or 6:26 attack, or uncontrolled 6:27 uncontrolled 6:27 uncontrolled blood pressure 6:28 blood pressure 6:28 blood pressure require 6:28 require 6:28 require consultation with 6:29 consultation with 6:29 consultation with a cardiologist before 6:29 a cardiologist before 6:29 a cardiologist before you even 6:30 you even 6:30 you even consider it. And it 6:31 consider it. And it 6:31 consider it. And it should not be combined with 6:32 should not be combined with 6:33 anemia drugs such as EPO. And 6:33 anemia drugs such as EPO. And pregnancy and 6:33 pregnancy and 6:33 pregnancy and breastfeeding, 6:34 breastfeeding, 6:34 breastfeeding, of course, have not been 6:35 of course, have not been 6:35 of course, have not been sufficiently studied 6:35 sufficiently studied . So what to do if
How to Track Results on ARA-290 6:36 . So what to do if 6:36 . So what to do if you and your doctor 6:37 you and your doctor 6:37 you and your doctor are using ARA 290? 6:38 are using ARA 290? 6:38 are using ARA 290? How do I know if it 6:39 How do I know if it 6:39 How do I know if it works? Therefore, 6:40 works? Therefore, 6:40 works? Therefore, monitoring 6:40 monitoring 6:40 monitoring is established even before the 6:41 is established even before the 6:41 is established even before the first dose. Now, just to be 6:42 first dose. Now, just to be 6:42 first dose. Now, just to be safe, there are 6:43 safe, there are 6:43 safe, there are some basic tests 6:44 some basic tests 6:44 some basic tests that I recommend you 6:45 that I recommend you 6:45 that I recommend you consider. This is a 6:45 consider. This is a 6:45 consider. This is a complete 6:46 complete 6:46 complete blood count, as well as 6:47 blood count, as well as 6:47 blood count, as well as kidney and 6:48 kidney and 6:48 kidney and liver function. And for 6:49 liver function. And for 6:49 liver function. And for added benefit, I 6:50 added benefit, I 6:50 added benefit, I want to track 6:50 want to track 6:50 want to track glycated 6:51 glycated 6:51 glycated hemoglobin, 6:52 hemoglobin, 6:52 hemoglobin, fasting glucose, and 6:53 fasting glucose, and 6:53 fasting glucose, and cholesterol levels, 6:53 cholesterol levels, 6:53 cholesterol levels, especially in patients 6:54 especially in patients 6:54 especially in patients with diabetes. Regarding 6:55 with diabetes. Regarding 6:55 with diabetes. Regarding nerve pain, it is worth 6:56 nerve pain, it is worth 6:56 nerve pain, it is worth paying attention to 6:57 paying attention to 6:57 paying attention to the questionnaires on 6:58 the questionnaires on 6:58 the questionnaires on pain and symptoms of 6:59 pain and symptoms of 6:59 pain and symptoms of small 7:00 small 7:00 small fiber neuropathy, as well as the 6- 7:00 fiber neuropathy, as well as the 6- minute 7:01 minute 7:01 minute walk test. And if 7:02 walk test. And if 7:02 walk test. And if the clinic offers an 7:02 the clinic offers an 7:03 the clinic offers an eye scan, 7:03 eye scan, 7:03 eye scan, do it, because it 7:04 do it, because it 7:04 do it, because it allows you to 7:04 allows you to 7:04 allows you to directly 7:05 directly 7:05 directly count nerve 7:06 count nerve 7:06 count nerve fibers. And you should 7:06 fibers. And you should 7:06 fibers. And you should get checked a 7:07 get checked a 7:07 get checked a month after 7:08 month after 7:08 month after completing the course, 7:08 completing the course, 7:08 completing the course, as some changes 7:09 as some changes 7:09 as some changes in the tests 7:09 in the tests 7:09 in the tests persisted even 7:10 persisted even 7:10 persisted even after the last 7:11 after the last 7:11 after the last injection. So, who is the
Who Is the Ideal Candidate 7:12 injection. So, who is the 7:12 injection. So, who is the best or 7:13 best or 7:13 best or ideal candidate 7:14 ideal candidate 7:14 ideal candidate for ARA 290? There 7:15 for ARA 290? There 7:15 for ARA 290? There is no direct answer to this 7:16 is no direct answer to this , because, again, 7:17 , because, again, 7:17 , because, again, the drug is not 7:17 the drug is not 7:17 the drug is not FDA approved. But 7:18 FDA approved. But 7:18 FDA approved. But the person who may 7:19 the person who may 7:19 the person who may benefit most 7:20 benefit most 7:20 benefit most from ARA 290 is 7:20 from ARA 290 is 7:20 from ARA 290 is someone with 7:21 someone with 7:21 someone with confirmed 7:22 confirmed 7:22 confirmed small 7:22 small 7:22 small fiber neuropathy, 7:23 fiber neuropathy, 7:23 fiber neuropathy, most likely due to 7:24 most likely due to 7:24 most likely due to sarcoidosis or diabetes, 7:24 sarcoidosis or diabetes, 7:25 sarcoidosis or diabetes, who is living with burning, 7:25 who is living with burning, 7:25 who is living with burning, tingling, or 7:26 tingling, or 7:26 tingling, or 7:28 autonomic symptoms that have 7:28 autonomic symptoms that have not been resolved with 7:29 not been resolved with 7:29 not been resolved with standard 7:29 standard 7:29 standard treatments. They have been 7:30 treatments. They have been 7:30 treatments. They have been examined by a doctor, have 7:31 examined by a doctor, have 7:31 examined by a doctor, have no history of 7:32 no history of 7:32 no history of cancer, unstable 7:33 cancer, unstable 7:33 cancer, unstable heart disease, are 7:34 heart disease, are 7:34 heart disease, are not pregnant, and have 7:35 not pregnant, and have 7:35 not pregnant, and have nerves left that 7:36 nerves left that 7:36 nerves left that can be repaired. 7:37 can be repaired. 7:37 can be repaired. Some people with 7:38 Some people with 7:38 Some people with type 2 diabetes and 7:39 type 2 diabetes and 7:39 type 2 diabetes and early neuropathy 7:40 early neuropathy 7:40 early neuropathy may get an 7:40 may get an 7:40 may get an additional 7:41 additional 7:41 additional metabolic bonus. 7:42 metabolic bonus. 7:42 metabolic bonus. Frankly, I haven't 7:42 Frankly, I haven't 7:43 Frankly, I haven't treated a large 7:43 treated a large 7:43 treated a large number of patients 7:44 number of patients 7:44 number of patients with 7:45 with 7:45 with small fiber neuropathy. I 7:45 small fiber neuropathy. I 7:45 small fiber neuropathy. I treated one 7:46 treated one 7:46 treated one patient and the 7:47 patient and the 7:47 patient and the results were 7:47 results were 7:47 results were amazing and I 7:48 amazing and I 7:48 amazing and I used ARA 290 in 7:49 used ARA 290 in 7:49 used ARA 290 in patients with 7:50 patients with 7:50 patients with common 7:50 common 7:50 common neuropathy along with 7:51 neuropathy along with 7:51 neuropathy along with nutrition, diet, 7:52 nutrition, diet, 7:52 nutrition, diet, physical therapy, 7:53 physical therapy, 7:53 physical therapy, regenerative 7:54 regenerative 7:54 regenerative injections and anything that 7:55 injections and anything that 7:55 injections and anything that can help such 7:56 can help such 7:56 can help such people. Again, 7:57 people. Again, 7:57 people. Again, this is not a guarantee 7:58 this is not a guarantee 7:58 this is not a guarantee , but if 7:59 , but if 7:59 , but if I see nerve pain, 8:00 I see nerve pain, 8:00 I see nerve pain, I think about ARA 290. 8:01 I think about ARA 290. 8:01 I think about ARA 290. Right now, healthy 8:02 Right now, healthy 8:02 Right now, healthy adults seeking 8:03 adults seeking 8:03 adults seeking rejuvenation, 8:03 rejuvenation, 8:03 rejuvenation, longevity, or 8:04 longevity, or 8:04 longevity, or recovery, as well as 8:05 recovery, as well as 8:05 recovery, as well as people with brain injuries 8:06 people with brain injuries , heart 8:06 , heart 8:06 , heart disease, 8:07 disease, 8:07 disease, chronic fatigue—this is 8:08 chronic fatigue—this is 8:08 chronic fatigue—this is a question for 8:08 a question for 8:08 a question for future research 8:09 future research , and human clinical 8:09 , and human clinical 8:09 , and human clinical trials have 8:10 trials have 8:10 trials have yet to 8:11 yet to 8:11 yet to answer whether it will be 8:12 answer whether it will be 8:12 answer whether it will be beneficial. So, if 8:13 beneficial. So, if 8:13 beneficial. So, if you have been living with 8:14 you have been living with 8:14 you have been living with neuropathy, 8:14 neuropathy, 8:14 neuropathy, burning, 8:15 burning, 8:15 burning, tingling, or 8:15 tingling, or 8:15 tingling, or nerve pain for years and have 8:16 nerve pain for years and have 8:16 nerve pain for years and have been told that nothing will 8:17 been told that nothing will 8:17 been told that nothing will help, the health of 8:18 help, the health of 8:18 help, the health of your nerves may 8:19 your nerves may 8:19 your nerves may be a key 8:20 be a key 8:20 be a key piece of the puzzle 8:21 piece of the puzzle that 8:21 that 8:21 that ARA 290 can help solve. It is 8:22 ARA 290 can help solve. It is 8:23 ARA 290 can help solve. It is worth researching and 8:23 worth researching and 8:23 worth researching and working with a 8:24 working with a 8:24 working with a professional who 8:25 professional who 8:25 professional who understands this 8:26 understands this 8:26 understands this peptide. If 8:27 peptide. If 8:27 peptide. If you found this analysis 8:27 you found this analysis 8:27 you found this analysis helpful, please 8:28 helpful, please 8:28 helpful, please like it 8:29 like it , subscribe for 8:29 , subscribe for 8:29 , subscribe for more 8:30 more 8:30 more science- 8:30 science- 8:30 science- based 8:31 based 8:31 based insights on 8:31 insights on 8:31 insights on hormones, peptides, and 8:32 hormones, peptides, and 8:32 hormones, peptides, and longevity medicine, 8:33 longevity medicine, 8:33 longevity medicine, and don't forget to 8:33 and don't forget to 8:33 and don't forget to visit 8:34 visit 8:34 visit Dr. 8:34 Dr. 8:34 Dr. Greg Jones' supplement store. 8:35 Greg Jones' supplement store. 8:35 Greg Jones' supplement store. The link will be in the 8:36 The link will be in the 8:36 The link will be in the video description below. 8:37 video description below. 8:37 video description below. And share this 8:37 And share this 8:37 And share this video with someone in 8:38 video with someone in 8:38 video with someone in your circle who 8:39 your circle who 8:39 your circle who might find it useful. 8:40 might find it useful. 8:40 might find it useful. Thank you for watching. I'm 8:41 Thank you for watching. I'm 8:41 Thank you for watching. I'm Dr. Greg Jones, and 8:42 Dr. Greg Jones, and 8:42 Dr. Greg Jones, and I'll see you in the 8:43 I'll see you in the 8:43 I'll see you in the next video.
Comments